Protagonist Therapeutics Inc.
PTGX | NASDAQ
$144.98
+$1.98 (+1.38%)
At close: Sep 21, 2026, 4:00 PM ET
$144.98
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Market Data
Market Cap $9.2B
Enterprise Value $8.55B
Beta 1.79
Average Volume 637.54K
Shares Outstanding (Diluted) 71.01M
Shares Change YoY 11.8%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US74366E1029
Price Performance
Price Change 1M -5.5%
Price Change 3M 21.9%
Price Change 6M 39.0%
Price Change YTD 66.3%
Price Change 1Y 124.7%
Price Change 3Y 747.3%
Price Change 5Y 670.8%
1M CAGR (ann.) -2.2%
1Y CAGR (ann.) 141.5%
5Y CAGR (ann.) 26.0%
All-Time CAGR 28.1%
Valuation
PE Ratio 140.76
Forward PE 102.66
PEG Ratio -0.14
Forward PEG -1.06
PS Ratio 33.06
Forward PS 48.40
PB Ratio 11.08
P/FCF Ratio 112.32
P/Adj. FCF Ratio 499.16
P/OCF Ratio 72.85
EV/Sales 30.32
EV/EBIT 101.38
EV/EBITDA 100.03
EV/FCF 103.00
Earnings Yield 0.7%
FCF Yield 0.9%
Adj. FCF Yield 0.2%
Financial Health
Net Cash $782.58M
Total Debt $9.22M
Cash & Short-Term Investments $782.58M
Total Assets $885.54M
Current Ratio 21.71
Quick Ratio 21.71
Debt / Equity Ratio 0.01
Debt / EBITDA 0.11
Debt / FCF 0.11
OCF / Debt 8.93
Interest Coverage 0.00
Altman Z-Score 126.60
Piotroski F-Score 6
Margins & Profitability
Gross Profit Margin 99.9%
Operating Profit Margin 20.7%
EBITDA Margin 30.3%
Net Profit Margin 29.4%
FCF Margin 29.4%
Adj. FCF Margin 6.6%
SBC / Revenue 17.7%
SBC Impact (per share) -77.5%
Returns
Return on Assets 9.4%
Return on Equity 12.0%
Return on Invested Capital 6.7%
Return on Capital Employed 6.9%
Return on Tangible Assets 9.4%
Historical Growth (CAGR)
Revenue CAGR 3Y -6.9%
Revenue CAGR 5Y 59.6%
Revenue CAGR 10Y 33.8%
EPS CAGR 3Y -54.8%
EPS CAGR 5Y 579.0%
EPS CAGR 10Y 37.5%
FCF CAGR 3Y -63.2%
FCF CAGR 5Y 213.9%
FCF CAGR 10Y 144.0%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 26
EPS Growth Next 3Y 52.1%
Revenue Growth Next 3Y 27.8%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) $2.43
EPS Growth Est (next Q) -491.9%
Revenue Est (next Q) $240.13M
Revenue Growth Est (next Q) 4996.0%
Fair Value Estimates
Graham Number $17.20
Graham Upside -88.1%
Lynch Fair Value $25.75
Lynch Upside -82.2%
Price Target $176.29
Price Target Upside 21.6%
Cash Flow
Operating Cash Flow $82.25M
Free Cash Flow $83.01M
Adj. Free Cash Flow $18.68M
FCF Per Share $2
OCF Per Share $1.99
OCF/S Ratio 46.5%
Income Statement
Revenue $281.99M
Gross Profit $281.59M
Operating Income $58.34M
EBITDA $85.48M
Net Income $82.91M
EPS (Diluted) $1.03
Revenue / Employee $2M
Profit / Employee $588.01K
Employees 141
Add to Watchlist
Select watchlists to add or remove PTGX